

# TABLE OF CONTENTS

February 8, 2010

No. 2175

## BUSINESS

- 1 JCR Aims at 20% Share for EPO Biosimilar: President Ashida  
- Aiming at Overseas Business Development through Alliance with GSK
- 2 DSP to Transfer Growth Hormone Business to JCR  
- DSP to Split Animal Health Products, Food & Speciality Products
- 3 Pregabalin to Drive Pfizer's Primary Case Business: Mr Harada  
- Synergetic Effects Expected from Merger with Wyeth in R&D
- 4 Kyowa Kirin Aims at Pharm. Sales of ¥225.0 Bil. in FY2012  
- Sales, Profits Down for Pharmaceutical Business in FY2009  
- Permax to Be Taken Over from Eli Lilly Japan
- 5 Zeria to Overcome NHI Price Cuts through Synergism with Tillotts: President Ibe
- 6 Price Cuts for Long-Listed Drugs to Harshly Hit Mochida: President Mochida
- 6 Januvia, Glactiv Ranked No. 1, 2 on Both GP, HP Markets
- 8 **BUSINESS NEWS IN BRIEF**  
- Fuso Inks Sub-License Agreement for OTS102 with Otsuka  
- Kaken to Take Over Marketing of Synphase from Tsumura
- 8 **Survey**  
- 1 in 5 Does Not Finish Full-Course Tamiflu Treatment

## GENERICS

- 9 **Commentary**  
- Number of Entrants into Market for Biosimilars Increases, But Barriers Are Still High
- 9 **GENERICS NEWS IN BRIEF**  
- Astellas Transfers Yet Another Product to Choseido

## REGULATORY

- 10 Criteria for FY2010 NHI Price Revision Approved by Chuikyo  
- Premium to Be Raised If Schizophrenia Is Treated with Two or Less Antipsychotics  
- *Chuikyo* to Continue Deliberations on Reimbursement Method for Anticancer Drugs
- 11 Ensure Thorough Understanding of New Pricing System Among Healthcare Providers: Mr Shoda  
- Mr Shoda Appreciates New Government's Growth Strategy

## TOPICS

- H1N1 Vaccine Arepanrix Prequalified by WHO: GSK
- 12 Actos, Glivec, Herceptin to Be Re-Priced for Market Expansion  
- Grounds for Premium for "True Clinical Benefits"
- 13 Re-Pricing of Tasigna, Sprycel "Appropriate": Mr Isobe
- 14 Rozerem Recommended for Approval
- 15 PMDA Needs Internal Renovation: Prof. Kami
- 15 Panel on Unapproved Drugs to Hold 1st Meeting
- 16 Medical Fees Up for the 1st Time in 10 Years, But Drug Prices Down 6.5%
- 18 Present Scientific Grounds for Combination Drugs
- 19 **REGULATORY NEWS IN BRIEF**  
- Gemzar Recommended for Approval for Breast Cancer  
- FDA Extends PDUFA Date for Sepracor's STEDESA NDA  
- Fluzone High-Dose Approved for Elderly Patients in the US: sanofi-aventis

## R&D

- 20 Takara Bio Accelerates Commercialization of Gene, Cell Therapy
- 20 JSCTR to Certify Clinical Trial Monitors
- 21 Collect Clinically Significant PGx Evidence: Dr Uyama

## MEDICAL DEVICES

- 21 **MEDICAL DEVICE NEWS IN BRIEF**  
- 4 Class C2 Med Devices Recommended for Reimbursement  
- Bayer to Transfer Antsens to Horiba

## SELF-MEDICATION

- 22 Loxoprofen-Based Switch OTC Drugs Approved
- 22 **SELF-MEDICATION NEWS IN BRIEF**  
- SSP Revises Full-Year Business Forecasts for FY2009 Upward

## ON THE MOVE

- 22 - Masami Okubo Appointed President of Asucome

## MEDICAL FACILITIES & NURSING CARE

- 23 *Koroshō* Negotiates Partial Cancellation on Vaccine Import

## NEW PRODUCTS

- 23 - Shionogi: Anti-Flu Agent Rapiacta